Core Viewpoint - Editas Medicine, Inc. announced a partial affirmation and partial vacate of a previous decision by the U.S. Court of Appeals regarding patent interference related to CRISPR/Cas9 editing, with the case remanded back to the Patent Trial and Appeal Board (PTAB) for further review [1] Group 1: Legal and Patent Developments - The U.S. Court of Appeals for the Federal Circuit has affirmed-in-part and vacated-in-part the PTAB's decision regarding patents for CRISPR/Cas9 editing in human cells involving the University of California, University of Vienna, Emmanuelle Charpentier, and the Broad Institute [1] - Editas Medicine's in-licensed patents covering CRISPR/Cas12a are not affected by this decision and are not involved in the ongoing interference proceedings [1] Group 2: Company Strategy and Intellectual Property - The company remains confident in the strength of its intellectual property (IP) portfolio, which is expected to generate significant value now and in the future [2] - Editas holds a large portfolio of foundational U.S. and international patents, including exclusive licenses for Cas9 and Cas12a patent estates, which are crucial for developing human medicines [2] - The foundational IP includes issued patents covering fundamental aspects of CRISPR/Cas12a and CRISPR/Cas9 gene editing in all human cells, essential for CRISPR-based medicines [2] Group 3: Company Mission and Focus - Editas Medicine is focused on translating the potential of CRISPR/Cas12a and CRISPR/Cas9 systems into a pipeline of in vivo medicines for serious diseases [3] - The company aims to discover, develop, manufacture, and commercialize transformative gene editing medicines for a broad class of diseases [3]

Cibus (CBUS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Carlo Broos - Interim CFOPeter Beetham - Co-Founder, President, COO & Interim CEOGreg Gocal - Co-Founder, EVP & Chief Scientific OfficerAustin Moeller - Director - Equity ResearchMatthew Venezia - Biotech Equity Research Associate Conference Call Participants Laurence Alexander - AnalystSameer Joshi - Senior Equity Research Analyst Operator Good afternoon and welcome to the CBIZ 1Q25 Earnings Call. All participants will be in a ...

Core Insights - Cibus is advancing its gene editing technologies, particularly in rice and canola, with a focus on herbicide tolerance and disease resistance traits, targeting a commercial launch by 2027 [1][2] - Positive regulatory developments in Ecuador and the U.S. validate Cibus' gene editing technologies, enhancing its commercial prospects [1][2][7] - The company reported a significant increase in net loss for Q1 2025, primarily due to a goodwill impairment, while also showing progress in revenue generation [8][9][24] Company Developments - Cibus has achieved positive results in its Sclerotinia resistance program, demonstrating multiple modes of action against the disease in canola [1][4] - The USDA-APHIS has designated Cibus' canola disease resistance traits as not regulated, reinforcing the regulatory status of its RTDS technologies [1][2][7] - The company is expanding its trait development pipeline, with successful field trials and customer agreements in rice, including collaborations with major rice seed companies [5][7] Financial Performance - For Q1 2025, Cibus reported revenue of $1.034 million, up from $0.545 million in the same period last year [23][24] - Research and development expenses were $11.8 million, slightly down from $12.0 million year-over-year, while selling, general, and administrative expenses increased to $9.9 million [8][24] - The net loss for the quarter was $49.4 million, compared to $27.0 million in the previous year, largely due to a $21.0 million goodwill impairment [8][9][24] Regulatory and Market Progress - The California Rice Commission approved the planting of gene-edited rice, marking a significant milestone for Cibus in the U.S. market [7][9] - EU member states have endorsed a negotiating mandate on the regulation of plants obtained by New Genomic Techniques, facilitating discussions for legislative adoption [1][7] - Cibus plans to deliver initial traits to customers in California and Latin America by mid-2025 and the end of 2025, respectively [7][9]

Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing. The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect® continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes. The companies' combined technologies deliver high gene insertion efficiencies and high cell viabilities, enabling a ...

Intellia Therapeutics (NTLA) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Brittany Chaves - Senior Manager, Investor RelationsJohn Leonard - President and Chief Executive OfficerDavid Lebwohl - EVP & Chief Medical OfficerEdward Dulac - EVP & CFOLili Nsongo - VP - Equity Research, BiotechnologyTroy Langford - Biotechnology Equity Research Vice President Conference Call Participants Gena Wang - AnalystNone - AnalystKostas Biliouris - Director - Biotech Equity AnalystLuca Issi - Senior B ...

Intellia Therapeutics (NTLA) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good morning, and welcome to the Intellia First Quarter twenty twenty five Financial Results Conference Call. My name is Drew, and I will be your conference operator today. Following formal remarks, we will open the call up for a question and answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. As a reminder, all participants ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion of the ongo ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en ...

-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low- density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation anticipated at a medical meeting in the second half of 2025- -CASGEVY® continues to gain momentum; more than 65 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 90 patients have had cells collected across all regions; new patient in ...

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine management will participate in the f ...